Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran in MCI and mild Alzheimer's disease
NCT03752294Phase 1Withdrawn
- Sponsor
- University of Rhode Island
- Start
- May 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of dabigatran in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by University of Rhode Island. Planned start May 2019; status: withdrawn.
02
Drugs
dabigatran
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT03752294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03752294.